Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
India may issue a warning over cough syrup exported by Marion Biotech linked to a death in Uzbekistan.
Read Full NewsIn a new trial, patients with PD-L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.
The agency also granted traditional approval to later-line nivolumab indications for certain adults with the disease.
1.
No Benefit for PD-1 Inhibitors in Certain Gastroesophageal Cancers, FDA Panel Says
2.
The response of bipolar patients to lithium may be predicted by ancestry.
3.
Daily physical activity, even at light intensities, linked to lower cancer risk
4.
How to keep your prostate healthy and lower your risk of developing serious problems
5.
In patients with advanced lung cancer, cemiplimab combined with chemotherapy extends life and enhances quality of life.
1.
Everything You Need to Know About RDW-CV: A Comprehensive Guide
2.
The Essential Roadmap for Nutritional Excellence in Head and Neck Cancer Care
3.
Reshaping the Battlefield Through Tumor Microenvironment Modulation for Cancer Therapy
4.
Octreotide's Efficacy in Reducing Transfusion Requirements in Angiodysplasia Bleeding
5.
Mechanistic Depth and Clinical Impact of Rusfertide, Onyvide, IV Avastin, and Pemfexy
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part V
2.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
3.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
4.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge